Clinical Trial Update: Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating daratumumab in relapsed/refractory multiple myeloma with renal impairment has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Hellenic Society of Hematology | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2023-08-28